Data

Statin use by people with cardiovascular diseases to prevent complications

See all data and research on:

What you should know about this indicator

Eligibility for statin therapy for secondary prevention was defined among individuals with a history of self-reported cardiovascular disease.

Statin use by people with cardiovascular diseases to prevent complications
Proportion of eligible individuals self-reporting use of statins for the secondary prevention of cardiovascular disease
Source
Marcus et al. (2022) – with minor processing by Our World in Data
Last updated
October 5, 2023
Date range
2019–2019
Unit
%

Sources and processing

This data is based on the following sources

Retrieved on
October 5, 2023
Citation
This is the citation of the original data obtained from the source, prior to any processing or adaptation by Our World in Data. To cite data downloaded from this page, please use the suggested citation given in Reuse This Work below.
Marcus ME, Manne-Goehler J, Theilmann M, Farzadfar F, Moghaddam SS, Keykhaei M, Hajebi A, Tschida S, Lemp JM, Aryal KK, Dunn M, Houehanou C, Bahendeka S, Rohloff P, Atun R, Bärnighausen TW, Geldsetzer P, Ramirez-Zea M, Chopra V, Heisler M, Davies JI, Huffman MD, Vollmer S, Flood D. Use of statins for the prevention of cardiovascular disease in 41 low-income and middle-income countries: a cross-sectional study of nationally representative, individual-level data. Lancet Glob Health. 2022 Mar;10(3):e369-e379. doi: 10.1016/S2214-109X(21)00551-9. PMID: 35180420; PMCID: PMC8896912.

How we process data at Our World in Data

All data and visualizations on Our World in Data rely on data sourced from one or several original data providers. Preparing this original data involves several processing steps. Depending on the data, this can include standardizing country names and world region definitions, converting units, calculating derived indicators such as per capita measures, as well as adding or adapting metadata such as the name or the description given to an indicator.

At the link below you can find a detailed description of the structure of our data pipeline, including links to all the code used to prepare data across Our World in Data.

Read about our data pipeline

Reuse this work

  • All data produced by third-party providers and made available by Our World in Data are subject to the license terms from the original providers. Our work would not be possible without the data providers we rely on, so we ask you to always cite them appropriately (see below). This is crucial to allow data providers to continue doing their work, enhancing, maintaining and updating valuable data.
  • All data, visualizations, and code produced by Our World in Data are completely open access under the Creative Commons BY license. You have the permission to use, distribute, and reproduce these in any medium, provided the source and authors are credited.

Citations

How to cite this page

To cite this page overall, including any descriptions, FAQs or explanations of the data authored by Our World in Data, please use the following citation:

“Data Page: Statin use by people with cardiovascular diseases to prevent complications”, part of the following publication: Saloni Dattani, Veronika Samborska, Hannah Ritchie and Max Roser (2023) - “Cardiovascular Diseases”. Data adapted from Marcus et al.. Retrieved from https://ourworldindata.org/grapher/use-of-statins-for-secondary-prevention-amongst-eligibible-individuals [online resource]
How to cite this data

In-line citationIf you have limited space (e.g. in data visualizations), you can use this abbreviated in-line citation:

Marcus et al. (2022) – with minor processing by Our World in Data

Full citation

Marcus et al. (2022) – with minor processing by Our World in Data. “Statin use by people with cardiovascular diseases to prevent complications” [dataset]. Marcus et al., “Use of statins for the prevention of cardiovascular disease in 41 low-income and middle-income countries.” [original data]. Retrieved December 10, 2024 from https://ourworldindata.org/grapher/use-of-statins-for-secondary-prevention-amongst-eligibible-individuals